People: Warner Chilcott Plc (WCRX.O)
WCRX.O on Nasdaq
19.69USD
17 Jun 2013
19.69USD
17 Jun 2013
Price Change (% chg)
$-0.21 (-1.06%)
$-0.21 (-1.06%)
Prev Close
$19.90
$19.90
Open
$20.09
$20.09
Day's High
$20.16
$20.16
Day's Low
$19.50
$19.50
Volume
5,140,162
5,140,162
Avg. Vol
6,843,759
6,843,759
52-wk High
$20.75
$20.75
52-wk Low
$10.85
$10.85
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John King |
64 | 2011 | Independent Non-Executive Chairman of the Board |
Roger Boissonneault |
64 | 2005 | President, Chief Executive Officer, Director |
Paul Herendeen |
57 | 2013 | Chief Financial Officer, Executive Vice President, Director |
Rochelle Fuhrmann |
43 | 2011 | Senior Vice President - Finance |
Andrew Fenton |
49 | 2012 | Senior Vice President, Chief Information Officer |
Leland Cross |
56 | 2001 | Senior Vice President - Technical Operations |
Herman Ellman |
65 | 2000 | Senior Vice President - Clinical Development |
Claire Gilligan |
51 | 2011 | Senior Vice President - Quality |
Michael Halstead |
39 | 2011 | Senior Vice President - Corporate Development |
Alvin Howard |
58 | 2005 | Senior Vice President - Regulatory Affairs |
Francisco Rodriguez |
53 | 2013 | Senior Vice President - Technical Operations |
James Bloem |
62 | 2006 | Independent Director |
John Connaughton |
47 | 2004 | Independent Director |
Patrick O'Sullivan |
71 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
John King |
Dr. John A. King, Ph.D., is Independent Non-Executive Chairman of the Board of Warner Chilcott Plc. He is a private investor. Dr. King served in positions of increasing responsibility with the Company’s predecessors for twenty-six years, most recently as Executive Chairman, a position he held from 2000 until January 5, 2005. |
Roger Boissonneault |
Mr. Roger M. Boissonneault is President, Chief Executive Officer and Director of Warner Chilcott PLC., since January 5, 2005. Mr. Boissonneault was appointed Chief Executive Officer and Director of one of the Company’s predecessors in September 2000. From 1996 to 2000, he served as President and Chief Operating Officer of the company acquired by the Company’s predecessor, which was also known as Warner Chilcott PLC, serving as a director from 1998 through 2000. From 1976 to 1996, Mr. Boissonneault served in various capacities with Warner-Lambert (now a part of Pfizer), including as Vice President, Female Healthcare, Director of Corporate Strategic Planning and Director of Obstetrics/Gynecology Marketing. |
Paul Herendeen |
Mr. Paul S. Herendeen is Chief Financial Officer, Executive Vice President, Director of Warner Chilcott PLC. He was appointed as Director of the Company on May 2, 2013. He has been Chief Financial Officer, Executive Vice President of the Company since April 1, 2005. He is responsible for finance, accounting and treasury functions. From April 2001 to March 2005, Mr. Herendeen was Executive Vice President and Chief Financial Officer of MedPointe Inc. From 1998 through March 2001, Mr. Herendeen served as Executive Vice President and Chief Financial Officer. Mr. Herendeen also served as a director of predecessor companies from 1996 through March 2001. |
Rochelle Fuhrmann |
Ms. Rochelle Fuhrmann is Senior Vice President - Finance of Warner Chilcott Plc. She is responsible for various corporate finance functions as well as investor relations. Ms. Fuhrmann joined the Company in June 2006 and held positions of increasing responsibility before her promotion to Senior Vice President in January 2011, including most recently, Vice President, Finance. Prior to joining the Company, Ms. Fuhrmann held various positions in finance, accounting policy, investor relations and marketing at AT&T, Inc., including most recently, Director, Accounting Policy. |
Andrew Fenton |
Mr. Andrew Fenton is Senior Vice President, Chief Information Officer of Warner Chillcott PLC. He is responsible for information technology strategy, infrastructure and operations. Mr. Fenton joined the Company in November 2005 and held positions of increasing responsibility before his promotion to Senior Vice President in January 2012, including most recently, Vice President, Chief Information Officer. Prior to joining the Company, Mr. Fenton held various positions in information technology at IBM Corporation, including most recently, Vice President, Global Relationship Partner. |
Leland Cross |
Mr. Leland H. Cross is Senior Vice President - Technical Operations of Warner Chilcott PLC, since September 1, 2001. He is responsible for technical operations worldwide. From 1994 to 2001, Mr. Cross was part of the Global Manufacturing group at Warner-Lambert (now part of Pfizer), where most recently he served as General Manager of Pfizer Ireland Pharmaceuticals, responsible for Pfizer’s dosage manufacturing operations in Ireland. Prior to joining Warner-Lambert, Mr. Cross managed a manufacturing operation for Merck & Co. Inc. |
Herman Ellman |
Dr. Herman Ellman, M.D., is Senior Vice President - Clinical Development of Warner Chilcott PLC, since June 2000. Dr. Ellman is responsible for clinical development and medical affairs activities. Prior to joining the Company, Dr. Ellman held the position of Medical Director for Women’s Healthcare at Berlex Laboratories. |
Claire Gilligan |
Dr. Claire A. Gilligan, Ph.D., is Senior Vice President - Quality of Warner Chilcott Plc. She is responsible for quality worldwide. Dr. Gilligan joined a predecessor of the Company in 1992 and has held positions of increasing responsibility at the Company since that time. From 2004 until her promotion to Senior Vice President in July 2010, Dr. Gilligan was Vice President of Pharmaceutical Development, during which time she was responsible for the development of all products and manufacturing processes. Prior to joining the Company, Dr. Gilligan lectured in the School of Pharmacy at the Queen’s University of Belfast. |
Michael Halstead |
Mr. Michael Halstead is Senior Vice President - Corporate Development of Warner Chilcott Plc. He is responsible for the Company’s business development efforts. Mr. Halstead joined the Company’s legal group in May 2005 and held positions of increasing responsibility before his promotion to his current position in June 2011. Prior to joining the Company, Mr. Halstead practiced law in the mergers and acquisitions group of Davis Polk & Wardwell LLP. |
Alvin Howard |
Mr. Alvin D. Howard is Senior Vice President - Regulatory Affairs of Warner Chilcott PLC., since August 1, 2005. He joined the Company as Vice President, Regulatory Affairs in February 2001. He is responsible for the registration of all products and for managing relationships with the U.S. Food and Drug Administration (“FDA”), Health Canada and other agencies regulating the sale of pharmaceutical products. Prior to joining the Company, Mr. Howard was Vice President, Worldwide Regulatory Affairs at Roberts Pharmaceuticals. |
Francisco Rodriguez |
Mr. Francisco Rodriguez is Senior Vice President - Technical Operations of Warner Chilcott PLC., since February 2013. He is responsible for the technical operations of the Company’s manufacturing facilities in Fajardo, Puerto Rico, Weiterstadt, Germany and Larne, Northern Ireland. Mr. Rodriguez joined the Company in March 2011 as General Manager of the Company’s Fajardo, Puerto Rico manufacturing facility. Prior to joining the Company, Mr. Rodriguez served as Vice President of Operations at Cephalon, Inc. from 2008 to 2011. Prior to joining Cephalon, Inc., Mr. Rodriguez worked for over 20 years in Schering-Plough Corporation’s (now Merck & Co., Inc.) product supply organization in positions of increasing responsibility. |
James Bloem |
Mr. James H. Bloem is Independent Director of Warner Chilcott PLC. He is the Director, is a Senior Vice President and the Chief Financial Officer of Humana Inc. (“Humana”), a position he has held since 2001. Humana is one of the nation’s health benefit companies with approximately 11.1 million medical members and approximately 7.3 million specialty-benefit members. Mr. Bloem also currently serves on the board of Rotech Healthcare, Inc. In addition, from 1996 to 2000, he served as a member of the board of directors of one of the Company’s predecessors. |
John Connaughton |
Mr. John P. Connaughton is Independent Director of Warner Chilcott PLC. He has served as a Managing Director of Bain Capital Partners, LLC (“BCP”) since 1997 and a member of the firm since 1989. Prior to joining BCP, Mr. Connaughton served as a consultant at Bain & Company, Inc. (“Bain & Co.”), where he worked in the healthcare, consumer products and business services industries. Mr. Connaughton also serves as a director of Hospital Corporation of America, Clear Channel Communications, Inc., Air Medical Group Holdings, Inc., Quintiles Transnational Corp. and The Boston Celtics. He also volunteers for a variety of charitable organizations, serving as a member of the Berklee College of Music Board of Trustees and the University of Virginia McIntire Foundation Board of Trustees. During the prior five years, Mr. Connaughton also previously served on the boards of CRC Health Group Inc., SunGard Data Systems, Warner Music Group, AMC Theatres, M|C Communications (PriMed) and Cumulus Media Partners. |
Patrick O'Sullivan |
Mr. Patrick J. O'Sullivan is Independent Director of Warner Chilcott Plc. He is a pharmaceutical business consultant. Prior to his retirement in 2006, Mr. O’Sullivan served in positions of increasing responsibility with LEO Pharma A/S (“LEO”) for more than thirty years, most recently as the Chief Executive Officer of LEO Pharma Ireland and as a director of LEO. He also served as a director of LEO Pharmaceuticals Ltd. UK, LEO Pharma SA France and The LEO Foundation. Mr. O’Sullivan is a registered pharmacist, a member and honorary fellow of the Pharmaceutical Society of Ireland and a Knight of the Order of the Dannebrog. Currently, Mr. O’Sullivan serves on the board of directors of Amarin Corporation plc, where he is a member of the audit committee, and on the boards of directors of Corsicato Ltd and Amarin Pharmaceuticals Ireland Ltd, each a subsidiary of Amarin Corporation plc. During the prior five years, Mr. O’Sullivan also served on the board of Merrion Pharmaceuticals Plc. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John King |
-- |
Roger Boissonneault |
6,623,870 |
Paul Herendeen |
2,439,330 |
Rochelle Fuhrmann |
-- |
Andrew Fenton |
-- |
Leland Cross |
2,643,990 |
Herman Ellman |
-- |
Claire Gilligan |
-- |
Michael Halstead |
-- |
Alvin Howard |
1,004,680 |
Francisco Rodriguez |
-- |
James Bloem |
-- |
John Connaughton |
-- |
Patrick O'Sullivan |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
John King |
0 | 0 |
Roger Boissonneault |
119,858 | 0 |
Paul Herendeen |
119,858 | 0 |
Rochelle Fuhrmann |
0 | 0 |
Andrew Fenton |
0 | 0 |
Leland Cross |
0 | 0 |
Herman Ellman |
0 | 0 |
Claire Gilligan |
0 | 0 |
Michael Halstead |
0 | 0 |
Alvin Howard |
0 | 0 |
Francisco Rodriguez |
0 | 0 |
James Bloem |
0 | 0 |
John Connaughton |
0 | 0 |
Patrick O'Sullivan |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
KING JOHN A |
4,170 | $0.00 |
BLOEM JAMES H |
4,170 | $0.00 |
O SULLIVAN PATRICK J |
4,170 | $0.00 |
HOWSON TAMAR D |
4,170 | $0.00 |
VAN ZOONEN MARINUS JOHANNES |
703 | $13.41 |
CONNAUGHTON JOHN P |
10,590,608 | $13.47 |
CONNAUGHTON JOHN P |
901,014 | $0.00 |
ELLMAN HERMAN |
1,666 | $13.38 |
FUHRMANN ROCHELLE |
1,728 | $13.46 |
RODRIGUEZ RAMA FRANCISCO |
820 | $13.46 |
HOWARD ALVIN D |
1,728 | $13.46 |
FENTON ANDREW |
1,390 | $13.46 |
BOISSONNEAULT ROGER M |
18,730 | $13.46 |
VAN ZOONEN MARINUS JOHANNES |
15,869 | $13.46 |
HALSTEAD MICHAEL |
1,747 | $13.46 |
GILLIGAN CLAIRE A |
2,354 | $13.46 |
HERENDEEN PAUL S |
4,674 | $13.46 |
CROSS LELAND H |
1,324 | $13.46 |
VAN ZOONEN MARINUS JOHANNES |
26,767 | $0.00 |
VAN ZOONEN MARINUS JOHANNES |
4,970 | $0.00 |
BOISSONNEAULT ROGER M |
7,928 | $14.53 |
HOWARD ALVIN D |
767 | $14.53 |
FENTON ANDREW |
419 | $14.53 |
HALSTEAD MICHAEL |
419 | $14.53 |
ELLMAN HERMAN |
691 | $14.53 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
